Literature DB >> 19918775

Acute-onset chronic inflammatory demyelinating polyneuropathy with cranial nerve involvement, dysautonomia, respiratory failure, and autoantibodies.

Philippe Hantson1, Luc Kevers, Nicole Fabien, Peter Van Den Bergh.   

Abstract

We examined a 27-year-old woman who developed rapidly progressive quadriplegia and acute respiratory failure that required mechanical ventilation in the intensive care unit. It was unclear whether this was a presentation of Guillain-Barré syndrome (GBS) or acute-onset chronic inflammatory demyelinating polyradiculoneuropathy (A-CIDP). Remarkable features included multiple cranial nerve involvement, respiratory failure, dysautonomia, and skin manifestations. Several autoantibodies were elevated, including antinuclear (ANA), anticardiolipin (aCL), thyroid, and calcium-sensing receptor (CaSR) autoantibodies. The patient was initially diagnosed with GBS and treated with intravenous immunoglobulin (IVIg). After almost complete recovery, relapse with quadriplegia and respiratory failure was observed 12 weeks after motor symptom onset. She then received IVIg and steroid pulse therapy followed by maintenance oral methylprednisolone and plasma exchange. She recovered completely 4 months after the relapse. The further clinical and serological course was consistent with systemic lupus erythematosus (SLE)-associated CIDP. Herein we evaluate the association between A-CIDP and some biological markers of autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19918775     DOI: 10.1002/mus.21543

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  5 in total

1.  Autonomic dysfunction in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  J J Figueroa; P J B Dyck; R S Laughlin; J A Mercado; R Massie; P Sandroni; P J Dyck; P A Low
Journal:  Neurology       Date:  2012-02-22       Impact factor: 9.910

2.  Severe Chronic Inflammatory Demyelinating Polyneuropathy Ameliorated following High-dose (3 g/kg) Intravenous Immunoglobulin Therapy.

Authors:  Yusuke Seino; Takumi Nakamura; Mie Hirohata; Takeshi Kawarabayashi; Toshimi Okushima; Mikio Shoji
Journal:  Intern Med       Date:  2018-11-19       Impact factor: 1.271

3.  Neuropsychiatric Lupus: The Devil is in the Detail.

Authors:  Arunmozhimaran Elavarasi; Mamta B Singh; Padma Srivastava; Vinay Goyal
Journal:  Ann Indian Acad Neurol       Date:  2019 Apr-Jun       Impact factor: 1.383

4.  The introspection on the diagnosis and treatment process of a case of Guillain-Barré syndrome (GBS) attributed to systemic lupus erythematosus (SLE): A case report.

Authors:  Nan Zhang; Jie Cao; Meng Zhao; Li Sun
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

5.  Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): An Uncommon Manifestation of Systemic Lupus Erythematosus (SLE).

Authors:  Hrudya Abraham; Jose Kuzhively; Syed W Rizvi
Journal:  Am J Case Rep       Date:  2017-09-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.